Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-22-002920
Filing Date
2022-11-03
Accepted
2022-11-03 08:45:29
Documents
46
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q clrb-20220930x10q.htm   iXBRL 10-Q 978345
2 EX-31.1 clrb-20220930xex31d1.htm EX-31.1 11910
3 EX-31.2 clrb-20220930xex31d2.htm EX-31.2 11908
4 EX-32.1 clrb-20220930xex32d1.htm EX-32.1 11339
  Complete submission text file 0001410578-22-002920.txt   3907978

Data Files

Seq Description Document Type Size
5 EX-101.SCH clrb-20220930.xsd EX-101.SCH 29407
6 EX-101.CAL clrb-20220930_cal.xml EX-101.CAL 24807
7 EX-101.DEF clrb-20220930_def.xml EX-101.DEF 128113
8 EX-101.LAB clrb-20220930_lab.xml EX-101.LAB 234283
9 EX-101.PRE clrb-20220930_pre.xml EX-101.PRE 200542
40 EXTRACTED XBRL INSTANCE DOCUMENT clrb-20220930x10q_htm.xml XML 579133
Mailing Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932 (608) 441-8120
Cellectar Biosciences, Inc. (Filer) CIK: 0001279704 (see all company filings)

EIN.: 043321804 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36598 | Film No.: 221356416
SIC: 2834 Pharmaceutical Preparations